Randomized clinical trial on the efficacy of Escherichia coli- derived rhBMP-2 with β-TCP/HA in extraction socket
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
PURPOSE. This randomized clinical trial was conducted to assess the safety and effectiveness of the ErhBMP-2 in alveolar bone regeneration as well as preservation of the β-TCP bone graft material that contains ErhBMP-2. MATERIALS AND METHODS. This study involved 72 patients at the 3 study centers. The patients, who were divided into 2 groups: the experiment group who had ErhBMP-2 coated TCP/HA and the control group who had TCP/HA graft material alone transplanted immediately after tooth extraction. CT was taken before and 3 months after the transplantation and healing status was compared between the two groups. The efficacy endpoints that were used to measure the degree of bone induction included alveolar bone height and 3 measurements of bone width. The paired t test was used to determine the significance of the changes (P<.05). RESULTS. Changes in alveolar bone height were -1.087± 1.413 mm in the control group and -.059± 0.960 mm in the experimental group (P<.01). At 25% extraction socket length [ESL], the changes were 0.006 ± 1.149 mm in the control group and 1.279 ± 1.387 mm in the experimental group. At 50% ESL, the changes were 0.542± 1.157 mm and 1.239± 1.249 mm, respectively (P<.01 for 25% ESL, and P<.05 for 50% ESL). During the experiment, no adverse reactions to the graft material were observed. CONCLUSION. ErhBMP-2 coated β-TCP/HA were found to be more effective in preserving alveolar bone than conventional β-TCP/HA alloplastic bone graft materials.
Abstract
PURPOSE. This randomized clinical trial was conducted to assess the safety and effectiveness of the ErhBMP-2 in alveolar bone regeneration as well as preservation of the β-TCP bone graft material that contains ErhBMP-2. MATERIALS AND METHODS. This study involved 72 patients at the 3 study centers. The patients, who were divided into 2 groups: the experiment group who had ErhBMP-2 coated TCP/HA and the control group who had TCP/HA graft material alone transplanted immediately after tooth extraction. CT was taken before and 3 months after the transplantation and healing status was compared between the two groups. The efficacy endpoints that were used to measure the degree of bone induction included alveolar bone height and 3 measurements of bone width. The paired t test was used to determine the significance of the changes (P<.05). RESULTS. Changes in alveolar bone height were -1.087± 1.413 mm in the control group and -.059± 0.960 mm in the experimental group (P<.01). At 25% extraction socket length [ESL], the changes were 0.006 ± 1.149 mm in the control group and 1.279 ± 1.387 mm in the experimental group. At 50% ESL, the changes were 0.542± 1.157 mm and 1.239± 1.249 mm, respectively (P<.01 for 25% ESL, and P<.05 for 50% ESL). During the experiment, no adverse reactions to the graft material were observed. CONCLUSION. ErhBMP-2 coated β-TCP/HA were found to be more effective in preserving alveolar bone than conventional β-TCP/HA alloplastic bone graft materials.
참고문헌 (18)
- Tallgren A, "Roentgen cephalometric analysis of ridge resorption and changes in jaw and occlusal relationships in immediate complete denture wearers", J Oral Rehabil, 7, pp.77~94 (1980)
- Jackson BJ, "Socket grafting: a predictable technique for site preservation", J Oral Implantol, 33, pp.353~364 (2007)
- John V, "Socket preservation as a precursor of future implant placement: review of the literature and case reports", Compend Contin Educ Dent, 28, pp.646~653 (2007)
- Reynolds MA, "The efficacy of bone replacement grafts in the treatment of periodontal osseous defects. A systematic review", Ann Periodontol, 8, pp.227~265 (2003)
- Szpalski M, "Applications of calcium phosphatebased cancellous bone void fillers in trauma surgery", Orthopedics, 25, pp.601~609 (2002)
- Urist MR, "Beta-tricalcium phosphate delivery system for bone morphogenetic protein", Clin Orthop Relat Res, 187, pp.277~280 (1984)
- Urist MR, "Bone: formation by autoinduction", Science, 150, pp.893~899 (1965)
- Bessa PC, "Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts)", J Tissue Eng Regen Med, 2, pp.1~13 (2008)
- Bessa PC, "Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery)", J Tissue Eng Regen Med, 2, pp.81~96 (2008)
- Wang EA, "Recombinant human bone morphogenetic protein induces bone formation", Proc Natl Acad Sci USA, 87, pp.2220~2224 (1990)
- Israel DI, "Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo", Growth Factors, 13, pp.291~300 (1996)
- Friedlaender GE, "Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions", J Bone Joint Surg Am, 83-A, pp.151~158 (2001)
- Burkus JK, "Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device", J Spinal Disord Tech, 16, pp.113~122 (2003)
- Bessho K, "Bone induction by Escherichia coli -derived recombinant human bone morphogenetic protein-2 compared with Chinese hamster ovary cell-derived recombinant human bone morphogenetic protein-2", Br J Oral Maxillofac Surg, 38, pp.645~649 (2000)
- Fiorellini JP, "Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation", J Periodontol, 76, pp.605~613 (2005)
- Einhorn TA, "A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair", J Bone Joint Surg Am, 85-A, pp.1425~1435 (2003)
- Cochran DL, "Evaluation of recombinant human bone morphogenetic protein- 2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans", J Periodontol, 71, pp.1241~1257 (2000)
- Howell TH, "A feasibility study evaluating rhBMP- 2", absorbable collagen sponge device for local alveolar ridge preservation or augmentation, 1997, pp.17, 124~139